Biofil Chemicals Pharmaceuticals Stock Current Valuation
| BIOFILCHEM | 42.78 2.81 6.16% |
Valuation analysis of Biofil Chemicals Pha helps investors to measure Biofil Chemicals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Biofil Chemicals' Cash And Short Term Investments are projected to increase significantly based on the last few years of reporting. The current year's Change In Cash is expected to grow to about 27.1 M, whereas Cash And Equivalents is forecasted to decline to about 222.3 K. Fundamental drivers impacting Biofil Chemicals' valuation include:
Price Book 4.033 | Enterprise Value 736.8 M | Enterprise Value Ebitda 62.4924 | Price Sales 1.7143 | Trailing PE 112.579 |
Overvalued
Today
Please note that Biofil Chemicals' price fluctuation is very steady at this time. Calculation of the real value of Biofil Chemicals Pha is based on 3 months time horizon. Increasing Biofil Chemicals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biofil Chemicals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biofil Stock. However, Biofil Chemicals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 42.78 | Real 39.69 | Hype 41.14 | Naive 46.43 |
The real value of Biofil Stock, also known as its intrinsic value, is the underlying worth of Biofil Chemicals Pha Company, which is reflected in its stock price. It is based on Biofil Chemicals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biofil Chemicals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biofil Chemicals Pharmaceuticals helps investors to forecast how Biofil stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biofil Chemicals more accurately as focusing exclusively on Biofil Chemicals' fundamentals will not take into account other important factors: Biofil Chemicals Pharmaceuticals Company Current Valuation Analysis
Biofil Chemicals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biofil Chemicals Current Valuation | 736.79 M |
Most of Biofil Chemicals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biofil Chemicals Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biofil Chemicals Pharmaceuticals has a Current Valuation of 736.79 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all India stocks is notably lower than that of the firm.
Biofil Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biofil Chemicals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biofil Chemicals could also be used in its relative valuation, which is a method of valuing Biofil Chemicals by comparing valuation metrics of similar companies.Biofil Chemicals is currently under evaluation in current valuation category among its peers.
Biofil Fundamentals
| Return On Equity | 0.04 | ||||
| Return On Asset | 0.0144 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 736.79 M | ||||
| Shares Outstanding | 16.27 M | ||||
| Shares Owned By Insiders | 59.77 % | ||||
| Price To Book | 4.03 X | ||||
| Price To Sales | 1.71 X | ||||
| Revenue | 400.35 M | ||||
| Gross Profit | 25.29 M | ||||
| EBITDA | 13.06 M | ||||
| Net Income | 7.09 M | ||||
| Cash And Equivalents | 260 K | ||||
| Total Debt | 4.39 M | ||||
| Book Value Per Share | 11.40 X | ||||
| Cash Flow From Operations | 23.94 M | ||||
| Earnings Per Share | 0.38 X | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.97 | ||||
| Market Capitalization | 696.19 M | ||||
| Total Asset | 470.83 M | ||||
| Retained Earnings | (316.94 M) | ||||
| Working Capital | 98.83 M | ||||
| Net Asset | 470.83 M |
About Biofil Chemicals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biofil Chemicals Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofil Chemicals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biofil Chemicals Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Biofil Stock
Biofil Chemicals financial ratios help investors to determine whether Biofil Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biofil with respect to the benefits of owning Biofil Chemicals security.